Chung Ming Hin, Chua Gilbert T, Leung Daniel, Chan Koon Wing, Nicholls John, Lau Yu Lung
Department of Pediatrics and Adolescent Medicine, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, Hong Kong SAR, China.
Department of Pediatrics and Adolescent Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, Hong Kong SAR, China.
Front Pediatr. 2022 Apr 14;10:794110. doi: 10.3389/fped.2022.794110. eCollection 2022.
X-linked lymphoproliferative disease (XLP1) is an inborn error of immunity (IEI) with severe immune dysregulation caused by a mutation in the gene resulting in the absence or dysfunction of signaling lymphocytic activation molecule (SLAM)-associated protein (SAP). The severe acute respiratory syndrome (SARS) caused by SARS-coronavirus (CoV), a highly pathogenic CoV, has been shown to only cause mild diseases in Asian children. We report on a 5-year-old Nepalese boy with agammaglobulinemia and probable SARS who died of diffuse alveolar damage 22 days after admission amid the SARS outbreak. The index patient and his younger brother were genetically confirmed to have XLP1. In the current coronavirus disease 2019 (COVID-19) pandemic, most children also had mild disease only. Children with severe COVID-19 would warrant investigations for underlying IEI, particularly along the pathways leading to immune dysregulation.
X连锁淋巴增生性疾病(XLP1)是一种免疫缺陷病(IEI),由于 基因发生突变,导致信号淋巴细胞激活分子(SLAM)相关蛋白(SAP)缺失或功能障碍,从而引起严重的免疫失调。由高致病性冠状病毒SARS-CoV引起的严重急性呼吸综合征(SARS),在亚洲儿童中仅引起轻症疾病。我们报告了一名5岁的尼泊尔男孩,他患有无丙种球蛋白血症,可能感染了SARS,在SARS疫情期间入院22天后死于弥漫性肺泡损伤。该索引患者及其弟弟经基因检测确诊患有XLP1。在当前的2019冠状病毒病(COVID-19)大流行中,大多数儿童也仅患轻症疾病。患有严重COVID-19的儿童有必要对潜在的免疫缺陷病进行调查,特别是沿着导致免疫失调的途径进行调查。